1. Academic Validation
  2. HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors

  • Elife. 2019 May 23;8:e46344. doi: 10.7554/eLife.46344.
Pratibha C Koneru 1 Ashwanth C Francis 2 Nanjie Deng 3 Stephanie V Rebensburg 1 Ashley C Hoyte 1 Jared Lindenberger 1 Daniel Adu-Ampratwum 4 Ross C Larue 4 Michael F Wempe 5 Alan N Engelman 6 7 Dmitry Lyumkis 8 James R Fuchs 4 Ronald M Levy 9 Gregory B Melikyan 2 Mamuka Kvaratskhelia 1
Affiliations

Affiliations

  • 1 Division of Infectious Diseases, School of Medicine, University of Colorado, Aurora, United States.
  • 2 Division of Infectious Diseases, Department of Pediatrics, Emory University, Atlanta, United States.
  • 3 Department of Chemistry and Physical Sciences, Pace University, New York, United States.
  • 4 College of Pharmacy, The Ohio State University, Columbus, United States.
  • 5 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, United States.
  • 6 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, United States.
  • 7 Department of Medicine, Harvard Medical School, Boston, United States.
  • 8 Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, United States.
  • 9 Department of Chemistry, Temple University, Philadelphia, United States.
Abstract

Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising new class of antiretroviral agents that disrupt proper viral maturation by inducing hyper-multimerization of IN. Here we show that lead pyridine-based ALLINI KF116 exhibits striking selectivity for IN tetramers versus lower order protein oligomers. IN structural features that are essential for its functional tetramerization and HIV-1 replication are also critically important for KF116 mediated higher-order IN multimerization. Live cell imaging of single viral particles revealed that KF116 treatment during virion production compromises the tight association of IN with capsid cores during subsequent Infection of target cells. We have synthesized the highly active (-)-KF116 enantiomer, which displayed EC50 of ~7 nM against wild type HIV-1 and ~10 fold higher, sub-nM activity against a clinically relevant dolutegravir resistant mutant virus suggesting potential clinical benefits for complementing dolutegravir therapy with pyridine-based ALLINIs.

Keywords

HIV-1; allosteric inhibitors; infectious disease; integrase; microbiology; virus.

Figures
Products